• Global pre-registrations have exceeded 1 million, drawing attention with its unique world and combat system using “cards”
• Various in-game rewards will be distributed based on the total number of pre-registrations, with the 4-star character “Amir” awarded upon reaching 2 million
• The Cover Song Contest with a total prize pool of 2,500 USD is accepting submissions until November 1st… Limited Playtest also scheduled

SEOUL, South Korea, Aug. 29, 2025 /PRNewswire/ — On Wednesday the 29th, Smilegate announced that global pre-registrations for its upcoming RPG “Chaos Zero Nightmare” (henceforth CZN), developed by Super Creative and serviced by Smilegate, have surpassed 1 million participants. Smilegate also announced plans to host an OST Cover Song Contest and a limited playtest.

CZN has surpassed 1 million pre-registrations, achieving the milestone in just about a month since pre-registration began on July 10th. Set in a dark world where humanity has been overtaken by a chaotic entity known as “Chaos,” CZN has drawn attention with its unique card-based combat system and emerged as one of the most anticipated titles of the second half of the year.

Smilegate will reward players with various in-game items as total pre-registrations reach certain milestones. If total pre-registrations surpass 2 million, all players will receive the 4-star character “Amir” as a reward.

To celebrate surpassing 1 million pre-registrations, Smilegate also released a celebratory illustration by well-known subculture artist KREN on its official social media channels.

An OST cover song contest with a total prize pool of 2,500 USD (approximately 3,500,000 KRW) will also be held, with submissions open until the coming November 1st. To participate, players must follow CZN’s official Twitter account and upload a video of themselves covering either the English or Japanese version of “OVER//RIDE” to their own account. The grand prize winner will receive 2 million KRW, with additional cash prizes awarded to the Excellence Award winners and Popularity Award winners. Notably, two participants will be selected to receive special merchandise, along with special messages, signed by Mori Calliope and Nerissa Ravencroft.

On the 22nd, Smilegate announced through a notice that it would be hosting a Limited Playtest for players. Further details on the Limited Playtest will be provided at a later date.

Kim Joo Hyung, Head of Business at Smilegate, stated, “Thanks to our players’ tremendous interest and support, pre-registrations have surpassed 1 million. We are sincerely grateful. As we head toward launch, we will do our utmost to deliver the title we have prepared for so long at its very best. We also ask for your participation in the Limited Playtest, for which we will share further details soon.”

For more information on Chaos Zero Nightmare, visit the official channels on X and YouTube, as well as Stove’s official site (https://chaoszeronightmare.onstove.com/en).

153 Rooms and 34 Villas Debut on Dong’ao Island, Offering a Secluded Luxury Experience in the Heart of the Greater Bay Area

ZHUHAI, China, Aug. 29, 2025 /PRNewswire/ — Amid the pristine waters and skies of Zhuhai’s Dong’ao Island, Ahn Luh Dong‘ao Island Zhuhai has formally opened, offering a retreat that blends Eastern traditions of seclusion with contemporary luxury. Developed by Huafa Group in collaboration with the Ahn Luh Lifestyle Academy, the property marks the brand’s debut in the Guangdong–Hong Kong–Macao Greater Bay Area. Inspired by the philosophy of “The Joy of Transcendence, the Journey of Discovery,” the resort sets a new benchmark for island hospitality in Zhuhai and highlights the role of Eastern design within the global luxury travel market, while contributing fresh momentum to the Greater Bay Area’s cultural and tourism sector.

Huafa and Ahn Luh Partner to Deliver a Distinctive Luxury Resort

The resort was developed by Huafa Group and is managed by Ahn Luh, an international lifestyle brand known for its emphasis on guest experience and quality. The project reflects Huafa’s broader commitment to marine culture and tourism while embodying Ahn Luh’s vision of secluded luxury.

Ahn Luh was co-founded by legendary hotelier Adrian Zecha, best known as founder of Aman, in partnership with Beijing Tourism Group. Renowned for combining Eastern aesthetics with a deep sense of retreat, the brand is consistently drawn to locations with strong natural and cultural resonance. The Dong’ao Island property represents both Ahn Luh’s first hotel in the Greater Bay Area and its first luxury island resort.

Ahn Luh Dong‘ao Island Zhuhai

Situated on the southern edge of Paijiao Bay, the property is perched atop dramatic cliffs on the island’s eastern coast and spans approximately 42,000 square meters. The resort features 153 guest rooms and 34 private villas. Dining experiences include Ahn Luh Brasserie (All-Day Dining) and Luh Chinese Restaurant. Amenities range from the Ahn Luh Academy -Teahouse and the Ahn Luh Spa to indoor and outdoor pools, a Tai Chi studio, and a fitness center. A multifunctional ballroom is available for events. Designed as an all-encompassing destination, the property seamlessly combines leisure travel, cultural discovery, waterfront activities, and business gatherings, offering guests a retreat that redefines the meaning of luxury.

Design Rooted in Culture and Landscape

The resort reflects both Huafa’s sustained commitment to luxury hospitality and Ahn Luh’s approach to lifestyles beyond luxury.

The project engaged several international design firms, with interiors led by Guangde Zhang, recipient of UNESCO’s Asia-Pacific Awards for Cultural Heritage Conservation. The design philosophy emphasizes simplicity, authenticity, and natural harmony, highlighting cultural depth, sustainable practices, and integration with the surrounding environment. Local materials and traditional motifs—including stone, waves, and Lingnan weaving—were incorporated throughout, creating an immersive environment where the landscape enters the room, and the room becomes part of the landscape. The resort has already been recognized with honors including the LIV Hospitality Design Awards (Luxury Resort), the French Novum Design Award for Innovation, and the MUSE Design Awards Gold (U.S.), affirming its excellence in cultural integration, design innovation, and architectural execution.

Immersive Experiences That Celebrate Culture and Wellness

More than a resort, Dong’ao Island Ahn Luh is envisioned as a destination that celebrates refined travel and cultural connection. Inspired by the principle of “culture as its soul,” the hotel introduces the Xiaoyao Wellness Program, which integrates practices such as morning Tai Chi and Himalayan salt baths with signature spa treatments. Culinary offerings draw inspiration from the Twenty-Four Solar Terms, presenting seasonal island-to-table menus. Curated cultural programming includes a sunrise ritual on the water, a traditional tea service inspired by the “Twelve Hours,” artisanal workshops at the Ahn Luh Academy, and performances at the Luh Stage. Together, these experiences invite global travelers to discover Eastern aesthetics within a contemporary luxury setting.

As the first Ahn Luh property in the Greater Bay Area, the resort is positioned as both a contribution to the region’s growing cultural and tourism industry and a showcase of Chinese cultural confidence in the global luxury hospitality arena.

DALLAS, Aug. 29, 2025 /PRNewswire/ — At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the International Trade Administration (TITA) and the Taiwan External Trade Development Council (TAITRA), highlighted Taiwan’s accelerating role in global digital health innovation. The pavilion brought together leading organizations introducing new approaches across telemedicine, artificial intelligence (AI), precision medicine, and next-generation medical services, as reported by GeneOnline.

One key highlight was CancerFree Biotech Ltd., which has advanced precision oncology through its blood-derived tumor organoid platform. Requiring only 20 milliliters of blood, the platform enables drug testing tailored to individual patients. By embedding AI into its workflow, CancerFree has cut testing time in half. The company’s recent collaboration with the Okinawa Institute of Science and Technology marks an important step in expanding applications in Japan.

In telemedicine, QT Medical, Inc. showcased its FDA-cleared PCA 500 portable 12-lead ECG system, extending hospital-grade diagnostics into homes, rural clinics, telehealth services, and clinical trials. Medimaging Integrated Solution Inc. (MiiS) presented its expertise in optical sensing and medical imaging processing, offering vertically integrated design and manufacturing from components to finished products. With an in-house regulatory team that secures approvals such as FDA clearance, MiiS positions itself as a one-stop solution provider. Stefan Cheng, President of MiiS, remarked “We aim to lead the future of AI-enabled medical diagnosis, emphasizing technologies like AI, robotics, and image sensing as essential for next-generation healthcare,”

Other exhibitors showcased how Taiwan is combining technical innovation with market-ready applications. imedtac Co., Ltd. introduced an AI-powered millimeter-wave radar system for non-contact monitoring of vital signs, such as respiration and heart rate, particularly valuable in eldercare and ICU settings facing labor shortages. Hukui Biotechnology Co., Ltd., a medical device CDMO founded in 2013, highlighted partnerships ranging from wireless ultrasound scanners to disposable endoscopes. The company also unveiled its patented “VitaShine Gamma Light”, designed to support dementia and Alzheimer’s prevention. Actively seeking distributors in the U.S., Hukui demonstrates how Taiwanese firms align contract manufacturing expertise with proprietary innovation.

These companies reinforced Taiwan’s ambition to be a trusted partner in advancing smart healthcare worldwide, blending AI, precision medicine, and device innovation into scalable global solutions. [Ad by TITA]

CHANGCHUN, China, Aug. 29, 2025 /PRNewswire/ — MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and JCBio Co., Ltd. (“JCBio”), a leading South Korean biotechnology company, have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project, a landmark collaboration. The initiative aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea. By combining MGI’s advanced omics technologies with JCBio’s local expertise, the partnership empowers researchers and clinicians while strengthening South Korea’s role as a regional leader in genomics and biotechnology.

Empowering South Korea’s Genomics Ecosystem

In an era where multi-omics research is reshaping healthcare, the collaboration between MGI Tech and JCBio marks a significant milestone in strengthening South Korea’s genomics ecosystem. By combining MGI’s proprietary short-read and long-read sequencing technologies, the initiative equips JCBio’s laboratories with end-to-end multi-omics capabilities, enabling researchers to tackle complex biological challenges with greater precision and efficiency.

Under the DCS Lab Project, JCBio is empowered to implement innovative sequencing strategies, advance integrated multi-omics analyses, explore novel sequencing applications, accelerate precision medicine, clinical translation, and AI-driven data insights—positioning the laboratory as a local hub for cutting-edge genomic research and multi-omics innovation.

The DCS Lab Initiative: Driving Frontier Science

Launched in 2023, MGI’s DCS Lab Initiative was established to empower international laboratories with comprehensive sequencing solutions. Named after MGI’s three core technologies—DNA genomics, Cell omics, and Spatial omics—the DCS Lab initiative is the company’s first global program targeting international laboratories with a focus on frontier science. It represents MGI’s unique capability within the industry to provide end-to-end products for applications ranging from DNA genomics to cell omics and spatial omics.

The initiative has already enabled pioneering research worldwide. At MGI’s Customer Experience Centre (CEC) in Australia, technologies such as DNBelab-C4 for single-cell omics and STOmics Stereo-seq for spatial transcriptomics have driven breakthroughs in cancer, medicine, and agriculture. Building on this success, MGI is now extending the program to South Korea in collaboration with JCBio—reinforcing the nation’s role as a key hub in Asia’s rapidly growing biotech ecosystem.

Executive Perspectives

“We are excited to partner with JCBio, an organization that shares our commitment to scientific excellence and innovation,” said Dr. Roy Tan, Director of MGI Northeast Asia. “With the DCS Lab Project, we are not only deploying sequencing platforms but establishing a hub for multi-omics discovery that equips South Korea’s research community with the tools to drive frontier science and improve human health.”

JCBio’s leadership emphasized the transformative nature of the collaboration:

“This partnership with MGI is a game-changer for South Korea’s research community,” added JaeChan Yoo, CEO of JCBio. “By integrating long- and short-read sequencing technologies, the DCS Lab enables researchers to tackle complex biological questions and accelerate breakthroughs in precision medicine and multi-omics research. Together, we are supporting South Korea’s growing role in global genomics research.”

About JCBio

Founded in 2005, JCBio has established itself as a key provider of research and diagnostic products in South Korea’s life sciences sector, with a mission to enhance longevity and improve quality of life.

For more information, please visit: https://jcbio.co.kr/company/greeting.php#  

About MGI

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.

Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

For more information, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.